Evidence map›Paper›PMID 32508014›Full record

ArticleClinical and translational medicine2020

Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury.

Marla R Wolfson, Perenlei Enkhbaatar, Satoshi Fukuda, Christina L Nelson, Robert O Williams, Soraya Hengsawas Surasarang, Sawittree Sahakijpijarn, Gennaro Calendo, Andrey A Komissarov, Galina Florova and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Marla R WolfsonDepartment of Thoracic Medicine & Surgery, Physiology & Pediatrics, and Temple Lung Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.
Perenlei EnkhbaatarDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Satoshi FukudaDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.ORCID https://orcid.org/0000-0003-3739-6494
Christina L NelsonDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Robert O WilliamsCollege of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Soraya Hengsawas SurasarangCollege of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Sawittree SahakijpijarnCollege of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Gennaro CalendoDepartment of Thoracic Medicine & Surgery, Physiology & Pediatrics, and Temple Lung Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.
Andrey A KomissarovCellular and Molecular Biology and the Texas Lung Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
Galina FlorovaCellular and Molecular Biology and the Texas Lung Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
Krishna SarvaCellular and Molecular Biology and the Texas Lung Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
Steven I IdellCellular and Molecular Biology and the Texas Lung Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
Thomas H ShafferDepartment of Thoracic Medicine & Surgery, Physiology & Pediatrics, and Temple Lung Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-1757-8506
Lung Institute · USAustin College · USThe University of Texas Medical Branch at Galveston · USTemple Lung Center · USAlfred I. duPont Hospital for Children · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEffective clinical management of airway clot and fibrinous cast formation of severe inhalational smoke-induced acute lung injury (ISALI) is lacking. Aerosolized delivery of tissue plasminogen activator (tPA) is confounded by airway bleeding; single-chain urokinase plasminogen activator (scuPA) moderated this adverse effect and supported transient improvement in gas exchange and lung mechanics. However, neither aerosolized plasminogen activator (PA) yielded durable improvements in physiologic responses or reduction in cast burden. Here, we hypothesized that perfluorochemical (PFC) liquids would facilitate PA distribution and sustain improvements in physiologic outcomes in ISALI.

methodsSpontaneously breathing adult sheep (n = 36) received anesthesia and analgesia and were instrumented, exposed to cotton smoke inhalation, and supported by mechanical ventilation for 48 h. Groups (n = 6/group) were studied without supplemental treatment, or, starting 4 h post injury, they received intratracheal low volume (8 mL) PFC liquid alone or a dose range of tPA/PFC or scuPA/PFC suspensions (4 or 8 mg in 8 mL PFC) every 8 h. Outcomes were evaluated by sequential measurements of cardiopulmonary parameters, lung histomorphology, and biochemical analyses of bronchoalveolar lavage fluid.

resultsDose-response and PA-type comparisons of outcomes demonstrated sustained superiority with low-volume PFC suspensions of scuPA over tPA or PFC alone, favoring the highest dose of scuPA/PFC suspension over lower doses, without airway bleeding.

conclusionsWe propose that this improved profile over previously reported aerosolized delivery is likely related to improved dose distribution. Sustained salutary responses to scuPA/PFC suspension delivery in this translational model are encouraging and support the possibility that the observed outcomes could be of clinical importance.

Indexed as

airway castsinhalational acute lung injuryperfluorochemicalsplasminogen activators

Identifiers

PMID32508014
PMCPMC7240845
OpenAlexW3033744433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.